Nociceptin/orphanin FQ receptor knockout rats: In vitro and in vivo studies

Neuropharmacology

Volumn 60, Issue 4, 2011, Pages 572-579

  Rizzi, Anna ^a,b   Molinari, Stefano ^a,b   Marti, Matteo ^a,b   Marzola, Giuliano ^a,b   Calo', Girolamo ^a,b  

^a UNIVERSITY OF FERRARA   (Italy)

^b National Institute of Neuroscience   (Italy)

Author keywords

Anxiety; Depression; Locomotor activity; Nociception; NOP receptor

Indexed keywords

FORMALDEHYDE; NOCICEPTIN RECEPTOR;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANXIETY; ARTICLE; CONTROLLED STUDY; DEPRESSION; EMOTIONALITY; FORCED SWIMMING TEST; IN VITRO STUDY; IN VIVO STUDY; LOCOMOTION; MALE; MAZE TEST; MOOD; MUSCLE TWITCH; NOCICEPTION; NONHUMAN; OPEN FIELD TEST; PRIORITY JOURNAL; PROTEIN FUNCTION; RAT; ROTAROD TEST; SIGNAL TRANSDUCTION; VAS DEFERENS;

ANALYSIS OF VARIANCE; ANIMALS; ANXIETY; BEHAVIOR, ANIMAL; DEPRESSION; DOSE-RESPONSE RELATIONSHIP, DRUG; ELECTRIC STIMULATION; MALE; MOTOR ACTIVITY; OPIOID PEPTIDES; RATS; RATS, TRANSGENIC; RECEPTORS, OPIOID; ROTAROD PERFORMANCE TEST; VAS DEFERENS;

EID: 79251594853     PISSN: 00283908     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.neuropharm.2010.12.010     Document Type: Article

References (57)

1. R. Bigoni, S. Giuliani, G. Calo', A. Rizzi, R. Guerrini, S. Salvadori, D. Regoli, and C.A. Maggi Characterization of nociceptin receptors in the periphery: in vitro and in vivo studies Naunyn Schmiedebergs Arch. Pharmacol. 359 1999 160 167
2. G. Calo', R. Guerrini, R. Bigoni, A. Rizzi, G. Marzola, H. Okawa, C. Bianchi, D.G. Lambert, S. Salvadori, and D. Regoli Characterization of [Nphe(1)]nociceptin(1-13)NH(2), a new selective nociceptin receptor antagonist Br. J. Pharmacol. 129 2000 1183 1193
3. G. Calo', A. Rizzi, D. Rizzi, R. Bigoni, R. Guerrini, G. Marzola, M. Marti, J. McDonald, M. Morari, D.G. Lambert, S. Salvadori, and D. Regoli [Nphe1, Arg14, Lys15]nociceptin-NH2, a novel potent and selective antagonist of the nociceptin/orphanin FQ receptor Br. J. Pharmacol. 136 2002 303 311
4. 2 (UFP-102), a highly potent and selective agonist of the nociceptin/orphanin FQ receptor J. Pharmacol. Exp. Ther. 312 2005 1114 1123
5. S. Chung, S. Pohl, J. Zeng, O. Civelli, and R.K. Reinscheid Endogenous orphanin FQ/nociceptin is involved in the development of morphine tolerance J. Pharmacol. Exp. Ther. 318 2006 262 267
6. U.B. Depner, R.K. Reinscheid, H. Takeshima, K. Brune, and H.U. Zeilhofer Normal sensitivity to acute pain, but increased inflammatory hyperalgesia in mice lacking the nociceptin precursor polypeptide or the nociceptin receptor Eur. J. Neurosci. 17 2003 2381 2387
7. M.J. Detke, M. Rickels, and I. Lucki Active behaviors in the rat forced swimming test differentially produced by serotonergic and noradrenergic antidepressants Psychopharmacology (Berl.) 121 1995 66 72
8. C. Fischetti, V. Camarda, A. Rizzi, M. Pela', C. Trapella, R. Guerrini, J. McDonald, D.G. Lambert, S. Salvadori, D. Regoli, and G. Calo' Pharmacological characterization of the nociceptin/orphanin FQ non peptide antagonist compound 24 Eur. J. Pharmacol. 614 2009 50 57
9. E.C. Gavioli, and G. Calo' Antidepressant- and anxiolytic-like effects of nociceptin/orphanin FQ receptor ligands Naunyn Schmiedebergs Arch. Pharmacol. 372 2006 319 330
10. E.C. Gavioli, F.S. Duarte, R. Guerrini, G. Calo', G.A. Rae, and T.C. M De Lima GABA(A) signalling is involved in N/OFQ anxiolytic-like effects but not in nocistatin anxiogenic-like action as evaluated in the mouse elevated plus maze Peptides 29 2008 1404 1412
11. E.C. Gavioli, G. Marzola, R. Guerrini, R. Bertorelli, S. Zucchini, T.C. De Lima, G.A. Rae, S. Salvadori, D. Regoli, and G. Calo' Blockade of nociceptin/orphanin FQ-NOP receptor signalling produces antidepressant-like effects: pharmacological and genetic evidences from the mouse forced swimming test Eur. J. Neurosci. 17 2003 1987 1990
12. E.C. Gavioli, G.A. Rae, G. Calo', R. Guerrini, and T.C. De Lima Central injections of nocistatin or its C-terminal hexapeptide exert anxiogenic-like effect on behaviour of mice in the plus-maze test Br. J. Pharmacol. 136 2002 764 772
13. E.C. Gavioli, A. Rizzi, G. Marzola, S. Zucchini, D. Regoli, and G. Calo' Altered anxiety-related behavior in nociceptin/orphanin FQ receptor gene knockout mice Peptides 27 2007 1229 1239
14. E.C. Gavioli, C.W. Vaughan, G. Marzola, R. Guerrini, V.A. Mitchell, S. Zucchini, T.C. De Lima, G.A. Rae, S. Salvadori, D. Regoli, and G. Calo' Antidepressant-like effects of the nociceptin/orphanin FQ receptor antagonist UFP-101: new evidence from rats and mice Naunyn Schmiedebergs Arch. Pharmacol. 369 2004 547 553
15. C. Goeldner, D. Reiss, B.L. Kieffer, and A.M. Ouagazzal Endogenous nociceptin/orphanin-FQ in the dorsal hippocampus facilitates despair-related behavior Hippocampus 20 2010 911 916
16. G. Griebel, G. Perrault, and D.J. Sanger Orphanin FQ, a novel neuropeptide with anti-stress-like activity Brain Res. 836 1999 221 224
17. H. Gu, D. Hu, X.R. Hong, J. Mao, Y. Cui, N. Hui, and J.Y. Sha Changes and significance of orphanin and serotonin in patients with postpartum depression Zhonghua Fu Chan Ke Za Zhi 38 2003 727 728
18. K. Hargreaves, R. Dubner, F. Brown, C. Flores, and J. Joris A new and sensitive method for measuring thermal nociception in cutaneous hyperalgesia Pain 32 1988 77 88
19. S. Hayashi, A. Hirao, H. Nakamura, K. Yamamura, K. Mizuno, and H. Yamashita Discovery of 1-[1-(1-methylcyclooctyl)-4-piperidinyl]-2-[(3R)-3- piperidinyl]-1H-benzimidazole: integrated drug-design and structure-activity relationships for orally potent, metabolically stable and potential-risk reduced novel non-peptide nociceptin/orphanin FQ receptor agonist as antianxiety drug Chem. Biol. Drug Des. 74 2009 369 381
20. A. Hirao, A. Imai, Y. Sugie, T. Tamura, H. Shimokawa, and K. Toide Pharmacological properties of a novel nociceptin/orphanin FQ receptor agonist, 2-(3,5-dimethylpiperazin-1-yl)-1-[1-(1-methylcyclooctyl)piperidin-4-yl] -1H-benzimidazole, with anxiolytic potential Eur. J. Pharmacol. 579 2008 189 195
21. J.R. Homberg, J.D. Mul, E. de Wit, and E. Cuppen Complete knockout of the nociceptin/orphanin FQ receptor in the rat does not induce compensatory changes in mu, delta and kappa opioid receptors Neuroscience 163 2009 308 315
22. F. Jenck, J.L. Moreau, J.R. Martin, G.J. Kilpatrick, R.K. Reinscheid, F.J. Monsma Jr., H.P. Nothacker, and O. Civelli Orphanin FQ acts as an anxiolytic to attenuate behavioral responses to stress Proc. Natl. Acad. Sci. U. S. A. 94 1997 14854 14858
23. F. Jenck, J. Wichmann, F.M. Dautzenberg, J.L. Moreau, A.M. Ouagazzal, J.R. Martin, K. Lundstrom, A.M. Cesura, S.M. Poli, S. Roever, S. Kolczewski, G. Adam, and G. Kilpatrick A synthetic agonist at the orphanin FQ/nociceptin receptor ORL1: anxiolytic profile in the rat Proc. Natl. Acad. Sci. U. S. A. 97 2000 4938 4943
24. J. Kamei, Y. Matsunawa, S. Miyata, S. Tanaka, and A. Saitoh Effects of nociceptin on the exploratory behavior of mice in the hole-board test Eur. J. Pharmacol. 489 2004 77 87
25. M.C. Ko, and N.N. Naughton Antinociceptive effects of nociceptin/orphanin FQ administered intrathecally in monkeys J. Pain 10 2009 509 516
26. M.C. Ko, H. Wei, J.H. Woods, and R.T. Kennedy Effects of intrathecally administered nociceptin/orphanin FQ in monkeys: behavioral and mass spectrometric studies J. Pharmacol. Exp. Ther. 318 2006 1257 1264
27. A. Koster, A. Montkowski, S. Schulz, E.M. Stube, K. Knaudt, F. Jenck, J.L. Moreau, H.P. Nothacker, O. Civelli, and R.K. Reinscheid Targeted disruption of the orphanin FQ/nociceptin gene increases stress susceptibility and impairs stress adaptation in mice Proc. Natl. Acad. Sci. U. S. A. 96 1999 10444 10449
28. D.G. Lambert The nociceptin/orphanin FQ receptor: a target with broad therapeutic potential Nat. Rev. Drug Discov. 7 2008 694 710
29. J.T. Liebel, D. Swandulla, and H.U. Zeilhofer Modulation of excitatory synaptic transmission by nociceptin in superficial dorsal horn neurones of the neonatal rat spinal cord Br. J. Pharmacol. 121 1997 425 432
30. C. Luo, E. Kumamoto, H. Furue, J. Chen, and M. Yoshimura Nociceptin inhibits excitatory but not inhibitory transmission to substantia gelatinosa neurones of adult rat spinal cord Neuroscience 109 2002 349 358
31. O.S. Mabrouk, M. Marti, and M. Morari Endogenous nociceptin/orphanin FQ (N/OFQ) contributes to haloperidol-induced changes of nigral amino acid transmission and parkinsonism: a combined microdialysis and behavioral study in naive and nociceptin/orphanin FQ receptor knockout mice Neuroscience 166 2010 40 48
32. M. Marti, F. Mela, M. Fantin, S. Zucchini, J.M. Brown, J. Witta, M. Di Benedetto, B. Buzas, R.K. Reinscheid, S. Salvadori, R. Guerrini, P. Romualdi, S. Candeletti, M. Simonato, B.M. Cox, and M. Morari Blockade of nociceptin/orphanin FQ transmission attenuates symptoms and neurodegeneration associated with Parkinson's disease J. Neurosci. 25 2005 9591 9601
33. M. Marti, F. Mela, C. Veronesi, R. Guerrini, S. Salvadori, M. Federici, N.B. Mercuri, A. Rizzi, G. Franchi, L. Beani, C. Bianchi, and M. Morari Blockade of nociceptin/orphanin FQ receptor signaling in rat substantia nigra pars reticulata stimulates nigrostriatal dopaminergic transmission and motor behavior J. Neurosci. 24 2004 6659 6666
34. M. Marti, S. Sarubbo, F. Latini, M. Cavallo, R. Eleopra, S. Biguzzi, C. Lettieri, C. Conti, M. Simonato, S. Zucchini, R. Quatrale, M. Sensi, S. Candeletti, P. Romualdi, and M. Morari Brain interstitial nociceptin/orphanin FQ levels are elevated in Parkinson's disease Mov. Disord 25 2010 1723 1732
35. M. Marti, C. Trapella, and M. Morari The novel nociceptin/orphanin FQ receptor antagonist trap-101 alleviates experimental parkinsonism through inhibition of the nigro-thalamic pathway: positive interaction with L-DOPA J. Neurochem. 107 2008 1683 1696
36. M. Nishi, T. Houtani, Y. Noda, T. Mamiya, K. Sato, T. Doi, J. Kuno, H. Takeshima, T. Nukada, T. Nabeshima, T. Yamashita, T. Noda, and T. Sugimoto Unrestrained nociceptive response and disregulation of hearing ability in mice lacking the nociceptin/orphaninFQ receptor EMBO J. 16 1997 1858 1864
37. S. Ozaki, H. Kawamoto, Y. Itoh, M. Miyaji, T. Azuma, D. Ichikawa, H. Nambu, T. Iguchi, Y. Iwasawa, and H. Ohta In vitro and in vivo pharmacological characterization of J-113397, a potent and selective non-peptidyl ORL1 receptor antagonist Eur. J. Pharmacol. 402 2000 45 53
38. S. Pellow, P. Chopin, S.E. File, and M. Briley Validation of open: closed arm entries in an elevated plus-maze as a measure of anxiety in the rat J. Neurosci. Methods 14 1985 149 167
39. J.P. Redrobe, G. Calo', D. Regoli, and R. Quirion Nociceptin receptor antagonists display antidepressant-like properties in the mouse forced swimming test Naunyn Schmiedebergs Arch. Pharmacol. 365 2002 164 167
40. A. Rizzi, E.C. Gavioli, G. Marzola, B. Spagnolo, S. Zucchini, R. Ciccocioppo, C. Trapella, D. Regoli, and G. Calo' Pharmacological characterization of the nociceptin/orphanin FQ receptor antagonist SB-612111 [(-)-cis-1-methyl-7-[[4-(2,6-dichlorophenyl)piperidin-1-yl]methyl]-6,7,8,9 -tetrahydro-5H-benzocyclohepten-5-ol]: in vivo studies J. Pharmacol. Exp. Ther. 321 2007 968 974
41. A. Rizzi, C. Nazzaro, G.G. Marzola, S. Zucchini, C. Trapella, R. Guerrini, H.U. Zeilhofer, D. Regoli, and G. Calo' Endogenous nociceptin/orphanin FQ signalling produces opposite spinal antinociceptive and supraspinal pronociceptive effects in the mouse formalin test: pharmacological and genetic evidences Pain 124 2006 100 108
42. G. Rozas, M.J. Guerra, and J.L. Labandeira-Garcia An automated rotarod method for quantitative drug-free evaluation of overall motor deficits in rat models of parkinsonism Brain Res. Brain Res. Protoc. 2 1997 75 84
43. T. Schallert, M. De Ryck, I.Q. Whishaw, V.D. Ramirez, and P. Teitelbaum Excessive bracing reactions and their control by atropine and L-DOPA in an animal analog of Parkinsonism Exp. Neurol. 64 1979 33 43
44. H. Uchiyama, T. Yamaguchi, A. Toda, T. Hiranita, S. Watanabe, and R. Eyanagi Involvement of the GABA/benzodiazepine receptor in the axiolytic-like effect of nociceptin/orphanin FQ Eur. J. Pharmacol. 590 2008 185 189
45. H. Ueda, T. Yamaguchi, S. Tokuyama, M. Inoue, M. Nishi, and H. Takeshima Partial loss of tolerance liability to morphine analgesia in mice lacking the nociceptin receptor gene Neurosci. Lett. 237 1997 136 138
46. G.B. Varty, L.A. Hyde, R.A. Hodgson, S.X. Lu, M.F. McCool, T.M. Kazdoba, R.A. Del Vecchio, D.H. Guthrie, A.J. Pond, M.E. Grzelak, X. Xu, W.A. Korfmacher, D. Tulshian, E.M. Parker, and G.A. Higgins Characterization of the nociceptin receptor (ORL-1) agonist, Ro64-6198, in tests of anxiety across multiple species Psychopharmacology (Berl.) 182 2005 132 143
47. G.B. Varty, S.X. Lu, C.A. Morgan, M.E. Cohen-Williams, R.A. Hodgson, A. Smith-Torhan, H. Zhang, A.B. Fawzi, M.P. Graziano, G.D. Ho, J. Matasi, D. Tulshian, V.L. Coffin, and G.J. Carey The anxiolytic-like effects of the novel, orally active nociceptin opioid receptor agonist 8-[bis(2-methylphenyl)methyl]- 3-phenyl-8-azabicyclo[3.2.1]octan-3-ol (SCH 221510) J. Pharmacol. Exp. Ther. 326 2008 672 682
48. R. Viaro, M. Marti, and M. Morari Dual motor response to l-dopa and nociceptin/orphanin FQ receptor antagonists in 1-methyl-4-phenyl-1,2,5,6- tetrahydropyridine (MPTP) treated mice: paradoxical inhibition is relieved by D(2)/D(3) receptor blockade Exp. Neurol. 223 2010 473 484
49. R. Viaro, R. Sanchez-Pernaute, M. Marti, C. Trapella, O. Isacson, and M. Morari Nociceptin/orphanin FQ receptor blockade attenuates MPTP-induced parkinsonism Neurobiol. Dis. 30 2008 430 438
50. N.P. Visanji, R.M. de Bie, T.H. Johnston, A.C. McCreary, J.M. Brotchie, and S.H. Fox The nociceptin/orphanin FQ (NOP) receptor antagonist J-113397 enhances the effects of levodopa in the MPTP-lesioned nonhuman primate model of Parkinson's disease Mov. Disord. 23 2008 1922 1925
51. G. Vitale, R. Arletti, V. Ruggieri, C. Cifani, and M. Massi Anxiolytic-like effects of nociceptin/orphanin FQ in the elevated plus maze and in the conditioned defensive burying test in rats Peptides 27 2006 2193 2200
52. 2 (UFP-101) reverses the behavioural and biochemical effects of unpredictable chronic mild stress in rats Psychopharmacology (Berl.) 207 2009 173 189
53. M. Volta, M. Marti, J. McDonald, S. Molinari, V. Camarda, M. Pela, C. Trapella, and M. Morari Pharmacological profile and antiparkinsonian properties of the novel nociceptin/orphanin FQ receptor antagonist 1-[1-cyclooctylmethyl-5- (1-hydroxy-1-methyl-ethyl)-1,2,3,6-tetrahydro-pyridin-4-y l]-3-ethyl-1,3- dihydro-benzoimidazol-2-one (GF-4) Peptides 31 2010 1194 1204
54. L.N. Wang, L.F. Liu, J.X. Zhang, and G.F. Zhao Plasma levels of nociceptin/orphanin FQ in patients with bipolar disorders and health adults Zhonghua Yi Xue Za Zhi 89 2009 916 918
55. T. Yamamoto, Y. Sakashita, and N. Nozaki-Taguchi Antagonism of ORLI receptor produces an algesic effect in the rat formalin test Neuroreport 12 2001 1323 1327
56. P.F. Zaratin, G. Petrone, M. Sbacchi, M. Garnier, C. Fossati, P. Petrillo, S. Ronzoni, G.A. Giardina, and M.A. Scheideler Modification of nociception and morphine tolerance by the selective opiate receptor-like orphan receptor antagonist (-)-cis-1-methyl-7-[[4-(2,6-dichlorophenyl)piperidin-1-yl] methyl]-6,7,8,9- tetrahydro-5H-benzocyclohepten-5-ol (SB-612111) J. Pharmacol. Exp. Ther. 308 2004 454 461
57. H.U. Zeilhofer, and G. Calo' Nociceptin/orphanin FQ and its receptor-potential targets for pain therapy? J. Pharmacol. Exp. Ther. 306 2003 423 429